JAGX - Jaguar Health, Inc. News

Discover

JAGX

Jaguar Health, Inc.

3.04

2 x 2.17

2 x 3.77

bid

ask

+

0.04

1.33%

2 @ 05:39 AM

3.04 +0.00 (0.00%)

Ytd	-90.67%
1y	-96.53%

2.86

day range

3.07

2.12

52 week range

97.65

Open	2.91	Prev Close	3.00	Low	2.86	High	3.07	Mkt Cap	14.65M
Vol	47.77K	Avg Vol	89.87K	EPS	-695.50	P/E	N/A	Forward P/E	-0.37
Beta	0.88	Short Ratio	1.12	Inst. Own	1.96%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	08-13	50-d Avg	4.40	200-d Avg	31.57	1yr Est	6.00

JAGX News

Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)

accessnewswire.com

Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Hea

Company remains sharply focused on its ongoing global development program for crofelemer for rare IF

Deal Dispatch: Penske Buys Vox Media's Digital Brands, AbbVie Acquires Apogee Therapeutics For $10.9 Billion, Camp Mystic Bankruptcy

Deal Dispatch: Penske Buys Vox Media's Digital Brands, AbbVie Acquires Apogee Therapeutics For $10.9

Major M&A deals this week include: Adobe buys Topaz Labs, Rise Baking Company purchases Jimmy&#3

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend

accessnewswire.com

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time

Company remains sharply focused on its ongoing global development program for crofelemer for rare in

Jaguar Health Submits New Animal Drug Application To FDA For Veterinary Medicine For Full Approval O

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the company has completed

Jaguar Health Board Initiates Process To Mull, Review Strategic Options

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that i

Jaguar Health Board Initiates Review Of Strategic Alternatives To Maximize Shareholder Value, Aligne

Reminder: Lisa Conte, Jaguar's founder & CEO, to present on June 24, 2026 at the Life Scienc

Jaguar Health Announces Data From Preclinical Study Initiates By Magdalena Biosciences Shows Novel E

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the results of a preclinic

Jaguar Health CEO To Present At Life Sciences Virtual Investor Forum

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, presid